Emmaus Life Sciences
Manufacturing · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
21250 Hawthorne Blvd Ste 800, Torrance, ...Phone Number
(310) 214-0065Website
www.emmausmedical.comRevenue
$28.5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About Emmaus Life Sciences
Emmaus Medical, Inc. is a biopharmaceutical company dedicated to improving the lives of individuals with rare and orphan diseases, particularly through their flagship product, Endari, which is a treatment for sickle cell disease. The company actively engages in the discovery, development, and commercialization of innovative therapies, with plans to target a broader range of conditions, including diverticulosis. Emmaus aims to cater to patients suffering from these significant health challenges, as well as healthcare providers and associations that support them. The company also emphasizes expanding its reach within the Middle East and North Africa regions, enhancing access to its treatments.Explore more
Emmaus Life Sciences Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Emmaus Life Sciences your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Emmaus Life Sciences had a recent Job posting/layoffs
Check if Emmaus Life Sciences has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Emmaus Life Sciences launches new products
Check out if Emmaus Life Sciences is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Emmaus Life Sciences
Earning: See what the market has to say on Emmaus Life Sciences recently announced quarterly report
Funding: Get notified immidiatlly once Emmaus Life Sciences has new funding data
Emmaus Life Sciences, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Recommended Actions
Reach out to Masked Content who joined Emmaus Life Sciences as Masked Content
Find more new buyers
Compare Similar Companies to Emmaus Life Sciences
Compare insights from companies similar to Emmaus Life Sciences, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Emmaus Life Sciences is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Emmaus Life Sciences is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Emmaus Life Sciences.
Emmaus Life Sciences financials insights
Gather financial insights about Emmaus Life Sciences, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Private Equity
$1.7M
Private Equity
$20M
2018
Debt
$30M
2019
Share Placement
$2.4M
2020
Share Placement
$25M
Debt
$350K
Emmaus Life Sciences Tech Stack
A closer look at the technologies used by Emmaus Life Sciences
See more technologies
Most Recent Scoops
Promotion
Executive Move
Executive Moves, Promotion
Earnings
Earnings
New Hire
Executive Move
Emmaus Life Sciences has announced that Corey Hebert has joined the organization as Chief Medical Officer. Previously, Hebert served as Chief Medical Officer at CareRx Inform.
Executive Moves, New Hire
Earnings
Earnings, Sales
Lateral Move
Executive Move
Board of Directors
Emmaus Life Sciences News & Media
Emmaus Life Sciences Reports Quarterly Financial Results
TORRANCE, Calif., Aug. 14, 2025 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the three and six...Emmaus Life Sciences Receives FDA Approval for Endari® Label Enhancements
Changes Based on Additional Pharmacokinetics Data TORRANCE, Calif., June 26, 2025 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, announced today that it has received Food and Drug Administration (FDA) approval for changes to the...Emmaus Life Sciences Reports Quarterly Financial Results
TORRANCE, Calif., May 15, 2025 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the three months...Emmaus Life Sciences Reports 2024 Financial Results
TORRANCE, Calif., April 14, 2025 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the year ended...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Emmaus Life Sciences
Sign Up For FreeTo access detailed company insights
Emmaus Medical, Inc. is a biopharmaceutical company dedicated to improving the lives of individuals with rare and orphan diseases, particularly through their flagship product, Endari, which is a treatment for sickle cell disease. The company actively engages in the discovery, development, and commercialization of innovative therapies, with plans to... Read More
